Latest & greatest articles for osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoarthritis

541. Exercise for osteoarthritis of the hip or knee. (Abstract)

Exercise for osteoarthritis of the hip or knee. Biomechanical factors, such as reduced muscle strength and joint mal-alignment, have an important role in the initiation and progression of osteoarthritis (OA) of the hip or knee. Currently, there is no known cure for OA, however, disease-related factors, such as impaired muscle function and reduced fitness, are potentially amenable to therapeutic exercise.To determine whether land-based therapeutic exercise is beneficial for people with OA (...) of the hip or knee in terms of reduced joint pain, improved physical function and/or the patient's global assessment of therapeutic effectiveness.Five databases (the Cochrane Controlled Trials Register, the Cochrane Musculoskeletal Group Trials Register, MEDLINE, CINAHL, PEDro) were searched up until November 2002.All randomized controlled trials comparing some form of land-based therapeutic exercise (as opposed to exercises conducted in the water) with a non-exercise group.Two reviewers independently

2003 Cochrane

542. Acupuncture for the pain management of osteoarthritis of the knee

and they did not synthesise the results of studies. Their conclusions may not, therefore, be reliable. Authors' objectives To assess the use of acupuncture in the treatment of osteoarthritis (OA) of the knee. Searching MEDLINE, CINAHL and Alt-Med (from 1977 to 2003) and the Cochrane CENTRAL Register were searched; the search terms were reported. The authors did not state whether they applied any language restrictions to their search strategy. Study selection Study designs of evaluations included (...) of osteoarthritis of the knee. Techniques in Orthopaedics 2003; 18(1): 33-36 Indexing Status Subject indexing assigned by CRD MeSH Acupuncture Analgesia; Arthralgia /therapy; Knee Joint; Osteoarthritis, Knee AccessionNumber 12003006683 Date bibliographic record published 31/08/2005 Date abstract record published 31/08/2005 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results

2003 DARE.

543. Intra-articular viscosupplementation for treatment of osteoarthritis of the knee

Services Advisory Committee. Intra-articular viscosupplementation for treatment of osteoarthritis of the knee. Canberra: Medical Services Advisory Committee (MSAC) 2003: 88 Authors' objectives This review aims to provide a systematic review of literature on intra-articular viscosupplementation for treatment of osteoarthritis (OA) of the knee. Authors' conclusions MSAC recommended that on the strength of evidence pertaining to intra-articular viscosupplementation for treatment of osteoarthritis (...) Intra-articular viscosupplementation for treatment of osteoarthritis of the knee Intra-articular viscosupplementation for treatment of osteoarthritis of the knee Intra-articular viscosupplementation for treatment of osteoarthritis of the knee Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical

2003 Health Technology Assessment (HTA) Database.

544. Structural and symptomatic efficacy of glucsamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis

Structural and symptomatic efficacy of glucsamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

545. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treament of knee osteoarthritis: a systematic review

osteoarthritis. The available evidence suggested that Hylan G-F 20 injections decreased pain and improved knee function in the short term. The authors' conclusions are supported by the data presented, but differences between included studies, suggest they should be viewed with caution. Authors' objectives To review the efficacy, effectiveness and safety of intra-articular injections of Hylan G-F 20 for the treatment of painful knee osteoarthritis (OA). Searching The manufacturers of Hylan G-F 20 supplied (...) ; n=386): a single course of Hylan G-F 20 produced a significant decrease of painful symptoms of knee OA (as measured on the visual analogue scale), and a short-term improvement in joint function (up to 3 to 6 months post-treatment). The authors noted that significant decreases in symptoms, compared with baseline, were often reported in both the treatment and control groups. Hylan G-F 20 versus NSAIDs and other conventional therapies (3 RCTs; n=407): 2 RCTs found no evidence that intra-articular

2003 DARE.

546. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam

Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac modified-release and piroxicam for 4 weeks, in the treatment of patients with osteoarthritis. The doses studied were 7.5 mg meloxicam once daily, 100 mg diclofenac

2003 NHS Economic Evaluation Database.

547. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis Full Text available with Trip Pro

; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal /adverse effects /economics /therapeutic use; Arthritis, Rheumatoid /drug therapy /physiopathology; Canada; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase Inhibitors /adverse effects /economics /therapeutic use; Drug Costs; Female; Gastrointestinal Diseases /chemically induced; Humans; Lactones /adverse effects /economics /therapeutic use; Male; Markov Chains; Middle Aged; Osteoarthritis /drug therapy /physiopathology; Pyrazoles; Quality (...) The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief

2003 NHS Economic Evaluation Database.

548. Acupuncture for osteoarthritis

Acupuncture for osteoarthritis Acupuncture for osteoarthritis Acupuncture for osteoarthritis Agency for Healthcare Research and Quality Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Agency for Healthcare Research and Quality. Acupuncture for osteoarthritis. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology (...) Assessment. 2003 Authors' objectives This review contains: a) A review of recent (1995 to present) systematic reviews on the use of acupuncture for osteoarthritis, updated with any RCTs published since the date of the last systematic review (2000 to present). b) Information available in the literature on training for persons performing this therapy and the number of physicians certified to perform this therapy. Authors' conclusions A key issue in studies of acupuncture is the effect of sham acupuncture

2003 Health Technology Assessment (HTA) Database.

549. Arthroscopic lavage for knee osteoarthritis

Arthroscopic lavage for knee osteoarthritis Arthroscopic lavage for knee osteoarthritis Arthroscopic lavage for knee osteoarthritis Allgood P Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Allgood P. Arthroscopic lavage for knee osteoarthritis. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2003: 10 (...) Authors' objectives This study aims to assess the effects of arthroscopic lavage, with or without debridement, in people with osteoarthritis of the knee. Authors' conclusions We found one good quality randomised controlled trial that was directly relevant to the question. It found that arthroscopic debridement and lavage did not improve pain and function compared with placebo in people with knee osteoarthritis. We found limited evidence that full arthroscopic lavage improves pain compared with low

2003 Health Technology Assessment (HTA) Database.

550. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis

Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

551. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare choice population

-specific inhibitors, oral celecoxib (Celebrex, Pharmacia Corporation) and oral rofecoxib (Vioxx, Merck & Co., Inc.), for the treatment of osteoarthritis (OA) in hypertensive patients aged 65 years or older. Celecoxib was administered at 200 mg/day and rofecoxib at 25 mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged 65 years or older who had OA and hypertension, and who were members of a Medicare Choice (...) sensitive combination was the costs of the cyclooxygenase-specific inhibitors and the physician visits. These could make the celecoxib costs slightly higher ($0.01 higher per patient per day) than those associated with rofecoxib. Synthesis of costs and benefits The health benefits and costs were not combined. Authors' conclusions The results suggested that celecoxib was a lower cost alternative to rofecoxib when treating osteoarthritis (OA) patients with hypertension, primarily because of the lower

2003 NHS Economic Evaluation Database.

552. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. (Abstract)

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2).To assess the relative therapeutic efficacy of rofecoxib, celecoxib, and acetaminophen in adults with OA.Randomized, parallel-group, double-blind trial, conducted from June 1999 to February 2000, in 29 clinical centers in the United (...) States.Three hundred eighty-two patients aged at least 40 years who had OA of the knee that was previously treated with NSAIDs or acetaminophen.Patients were randomly assigned to receive rofecoxib, 12.5 mg/d (n = 96); rofecoxib, 25 mg/d (n = 95); celecoxib, 200 mg/d (n = 97); or acetaminophen, 4000 mg/d (n = 94) for 6 weeks.Assessments over days 1 to 6 and over 6 weeks included pain on walking, night pain, pain at rest, and morning stiffness as measured on a Western Ontario McMaster Universities

2002 JAMA Controlled trial quality: predicted high

553. Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. Full Text available with Trip Pro

Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. To determine whether a home based exercise programme can improve outcomes in patients with knee pain.Pragmatic, factorial randomised controlled trial of two years' duration.Two general practices in Nottingham.786 men and women aged >/=45 years with self reported knee pain.Participants were randomised to four groups to receive exercise therapy, monthly telephone contact, exercise therapy plus (...) telephone contact, or no intervention. Patients in the no intervention and combined exercise and telephone groups were randomised to receive or not receive a placebo health food tablet.Primary outcome was self reported score for knee pain on the Western Ontario and McMaster universities (WOMAC) osteoarthritis index at two years. Secondary outcomes included knee specific physical function and stiffness (scored on WOMAC index), general physical function (scored on SF-36 questionnaire), psychological

2002 BMJ Controlled trial quality: predicted high

554. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. (Abstract)

A controlled trial of arthroscopic surgery for osteoarthritis of the knee. Many patients report symptomatic relief after undergoing arthroscopy of the knee for osteoarthritis, but it is unclear how the procedure achieves this result. We conducted a randomized, placebo-controlled trial to evaluate the efficacy of arthroscopy for osteoarthritis of the knee.A total of 180 patients with osteoarthritis of the knee were randomly assigned to receive arthroscopic débridement, arthroscopic lavage (...) , and 51.4+/-23.2, respectively, at two years (P=0.64 and P=0.96, respectively). Furthermore, the 95 percent confidence intervals for the differences between the placebo group and the intervention groups exclude any clinically meaningful difference.In this controlled trial involving patients with osteoarthritis of the knee, the outcomes after arthroscopic lavage or arthroscopic débridement were no better than those after a placebo procedure.

2002 NEJM Controlled trial quality: predicted high

555. Electromagnetic fields for the treatment of osteoarthritis. (Abstract)

Electromagnetic fields for the treatment of osteoarthritis. As the focus for osteoarthritis (OA) treatment shifts away from drug therapy, we consider the effectiveness of pulsed electric stimulation which is proven to stimulate cartilage growth on the cellular level.1)To assess the effectiveness of pulsed electric stimulation for the treatment of osteoarthritis (OA). 2) To assess the most effective and efficient method of applying an electromagnetic field, through pulsed electromagnetic fields (...) reviewers using a validated scale (Jadad 1996). Osteoarthritis outcome measures were extracted from the publications according to OMERACT guidelines (Bellamy 1997) and additional secondary outcomes considered.Only three studies with a total of 259 OA patients were included in the review. Electrical stimulation therapy had a small to moderate effect on outcomes for knee OA, all statistically significant with clinical benefit ranging from 13-23% greater with active treatment than with placebo. Only 2

2002 Cochrane

556. Effectiveness of psychoeducational interventions in osteoarthritis

included in the review Studies of patients with osteoarthritis were eligible for the review. Some of the included studies evaluated specifically overweight individuals, individuals on low incomes or who lived in inner cities, and community-dwelling adults, as well as those with site-specific osteoarthritis. Studies of patients with rheumatoid arthritis, or a mix of patients with either rheumatoid arthritis or osteoarthritis, were mentioned briefly in the review but were not incorporated (...) Effectiveness of psychoeducational interventions in osteoarthritis Effectiveness of psychoeducational interventions in osteoarthritis Effectiveness of psychoeducational interventions in osteoarthritis Marks R, Allegrante J P Authors' objectives To evaluate the effectiveness of psychoeducational interventions in patients suffering from osteoarthritis. Searching MEDLINE (from 1966 to 2002) and CINAHL (from 1982 to 2002) were searched for studies published as full reports in English; the keywords

2002 DARE.

557. Cox-II inhibitors versus non-steroidal anti-inflammatory drugs in rheumatoid and osteoarthritis patients: gastrointestinal effects

with rheumatoid arthritis or osteoarthritis. Authors' conclusions Identified studies suggest that cox-II inhibitors are associated with a slightly reduced risk of gastrointestinal adverse events compared with NSAIDs. However, the reliability of the conclusion is limited by low power for detecting adverse effects. In many cases, adequate power was achieved by pooling results from different exposure groups (receiving different NSAIDs or different doses). This prevents direct comparison of adverse effects (...) inhibitors was not reported (in the NICE review) or not allowed (in the subsequent RCTs). We cannot, therefore, reliably answer the clinically important question of whether cox-II inhibitors reduce gastrointestinal adverse effects compared with combined therapy with NSAIDs plus H2 antagonists or proton pump inhibitors. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Osteoarthritis Language

2002 Health Technology Assessment (HTA) Database.

558. S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease

S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease Hardy M, Coulter I, Morton S C, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig L K, Roth E A, Suttorp M J, Shekelle P Authors' objectives To perform a comprehensive literature review and synthesis of evidence (...) on the use of S-adenosyl-L-methionine (SAMe) for the treatment of depression, osteoarthritis and liver disease. Searching Five extensive searches were conducted of 25 named databases using a search strategy that was provided in an appendix to the review. There were no language restrictions. The reference lists of retrieved articles were searched for additional relevant studies. Study selection Study designs of evaluations included in the review The inclusion criteria specified the inclusion of randomised

2002 DARE.

559. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results

drawn. Health technology The study examined viscosupplementation with hylan G-F 20 for the treatment of osteoarthritis (OA) of the knee in Canada. The comparator was treatment without hylan G-F 20 Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population included ambulatory patients over 40 years old in Canada with a primary diagnosis of radiologically verified OA in the study knee (knee most symptomatic or with the most predominant (...) A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation

2002 NHS Economic Evaluation Database.

560. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis

Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Maetzel A, Krahn M, Naglie G. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Overview Issue 6. 2002 Authors' objectives The purpose of this assessment is to evaluate the long-term cost-effectiveness of the COX2 NSAID celecoxib, in comparison to diclofenac and ibuprofen, and rofecoxib in comparison to naproxen

2002 Health Technology Assessment (HTA) Database.